[go: up one dir, main page]

MX2019011869A - Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. - Google Patents

Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.

Info

Publication number
MX2019011869A
MX2019011869A MX2019011869A MX2019011869A MX2019011869A MX 2019011869 A MX2019011869 A MX 2019011869A MX 2019011869 A MX2019011869 A MX 2019011869A MX 2019011869 A MX2019011869 A MX 2019011869A MX 2019011869 A MX2019011869 A MX 2019011869A
Authority
MX
Mexico
Prior art keywords
paramixovirus
self
assemblies
pneumovirus
proteins
Prior art date
Application number
MX2019011869A
Other languages
English (en)
Inventor
Baker David
P King Neil
Nickerson Brooke
Joseph Stewart Lance
Perez Laurent
Lanzavecchia Antonio
Marcandalli Jessica
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2019011869A publication Critical patent/MX2019011869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

El presente documento describe nanoestructuras y su uso, en donde las nanoestructuras incluyen (a) una pluralidad de primeros ensamblajes, cada primer ensamblaje comprende una pluralidad de primeros polipéptidos idénticos; (b) una pluralidad de segundos ensamblajes, cada segundo ensamblaje comprende una pluralidad de segundos polipéptidos idénticos, en donde el segundo polipéptido difiere del primer polipéptido; en donde la pluralidad de primeros ensamblajes interactúa de manera no covalente con la pluralidad de segundos ensamblajes para formar una nanoestructura; y en donde la nanoestructura muestra múltiples copias de una o más proteínas F de paramixovirus y/o neumovirus o fragmentos antigénicos de las mismas, en un exterior de la nanoestructura.
MX2019011869A 2017-04-04 2018-04-03 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. MX2019011869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04
PCT/US2018/025880 WO2018187325A1 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Publications (1)

Publication Number Publication Date
MX2019011869A true MX2019011869A (es) 2020-01-09

Family

ID=62116943

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019011869A MX2019011869A (es) 2017-04-04 2018-04-03 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
MX2023004704A MX2023004704A (es) 2017-04-04 2019-10-02 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023004704A MX2023004704A (es) 2017-04-04 2019-10-02 Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.

Country Status (23)

Country Link
US (4) US11192926B2 (es)
EP (2) EP3606942B1 (es)
JP (3) JP7168938B2 (es)
KR (2) KR102774312B1 (es)
CN (3) CN115947873A (es)
AU (3) AU2018249533C1 (es)
BR (1) BR112019020661A2 (es)
CA (1) CA3058794A1 (es)
DK (1) DK3606942T3 (es)
ES (1) ES3040563T3 (es)
FI (1) FI3606942T3 (es)
HR (1) HRP20251060T1 (es)
IL (2) IL322023A (es)
LT (1) LT3606942T (es)
MX (2) MX2019011869A (es)
PH (1) PH12019502276A1 (es)
PL (1) PL3606942T3 (es)
PT (1) PT3606942T (es)
RS (1) RS67190B1 (es)
SG (1) SG11201908999QA (es)
SI (1) SI3606942T1 (es)
SM (1) SMT202500317T1 (es)
WO (1) WO2018187325A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
KR20250067954A (ko) 2018-02-28 2025-05-15 유니버시티 오브 워싱톤 자기 조립 나노구조 백신
EP3921332A2 (en) 2019-02-08 2021-12-15 The USA, as represented by The Secretary, Department of Health and Human Services Nanoparticle-based influenza virus vaccines and uses thereof
EP4025587A1 (en) * 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
MX2022009429A (es) * 2020-01-30 2022-08-25 Modernatx Inc Composiciones para la inmunizacion contra virus respiratorios.
PH12022552099A1 (en) * 2020-02-14 2024-01-29 Univ Washington Polypeptides, compositions, and their use to treat or limit development of an infection
AU2021220958A1 (en) * 2020-02-14 2022-09-01 University Of Washington Polypeptides and their use
MX2022015593A (es) * 2020-06-09 2023-04-03 Icosavax Inc Metodo de ensamblaje de particulas similares a virus de dos componentes.
US20240050559A1 (en) * 2020-06-09 2024-02-15 Icosavax, Inc. Method of making virus-like particle
KR102860080B1 (ko) 2020-10-09 2025-09-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 융합전-안정화된 hmpv f 단백질
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
IL302755A (en) 2020-11-13 2023-07-01 Icosavax Inc Protein-based nanoparticle vaccine for metapneumovirus
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
AU2022326546A1 (en) * 2021-08-10 2024-02-15 Icosavax, Inc. Virus-like particle vaccine for respiratory syncytial virus
CA3253853A1 (en) 2022-05-17 2023-11-23 Icosavax, Inc. MULTIVALENT VACCINE AGAINST PARAMYXOVIRUS AND ITS USES
CN120435313A (zh) * 2022-11-29 2025-08-05 斯克里普斯研究学院 包含新的纳米粒支架的疫苗
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
US20250041400A1 (en) * 2023-07-18 2025-02-06 Astrazeneca Ab Rsv vaccine
CN119930762A (zh) * 2023-11-03 2025-05-06 广东蓝玉生物科技有限公司 非洲猪瘟病毒ep153r蛋白的免疫原性组合物及其应用
WO2025093041A1 (zh) * 2023-11-03 2025-05-08 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
ES2237911T3 (es) 1998-03-04 2005-08-01 Exxonmobil Chemical Patents Inc. Aniones no coordinantes para polimerizacion de olefinas.
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
US20040005672A1 (en) 2002-02-22 2004-01-08 Santi Daniel V. Heterologous production of polyketides
EP1527160A4 (en) 2002-07-31 2005-09-14 Univ Leland Stanford Junior PREPARATION OF GLYCOSYLATED MACROLIDES IN E. COLI
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CA2580921C (en) 2004-09-21 2016-04-12 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
PL2222710T3 (pl) 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
EP2370099B1 (en) 2008-12-09 2016-04-20 Novavax, Inc. Modified rsv f proteins and methods of their use
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CA2799934C (en) 2010-07-07 2020-01-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
CN105381457A (zh) 2011-09-30 2016-03-09 诺瓦瓦克斯股份有限公司 用于呼吸道合胞病毒的重组纳米颗粒rsv f疫苗
WO2013056122A1 (en) 2011-10-12 2013-04-18 University Of Washington Engineered outer domain (eod) of hv gp120 and mutants thereof
JP2015514132A (ja) 2012-04-10 2015-05-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CA2879915C (en) 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
HRP20240996T1 (hr) 2013-03-13 2024-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefuzija rsv f proteina i njihova uporaba
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
WO2014139476A1 (zh) 2013-03-15 2014-09-18 厦门大学 Rsv融合蛋白的表位以及识别其的抗体
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
CN104436202B (zh) 2013-09-12 2017-07-28 中国科学院深圳先进技术研究院 聚合物纳米颗粒、其制备方法及疫苗组合物、疫苗制剂及其制备方法
WO2015048149A1 (en) 2013-09-24 2015-04-02 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP3092245B1 (en) 2014-01-09 2018-10-17 Alpha-o Peptides AG Flagellin-containing protein nanoparticles as a vaccine platform
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CN107074912B (zh) 2014-07-10 2021-10-29 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
EP3821906A1 (en) 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2017027480A1 (en) 2015-08-13 2017-02-16 Echogen Power Systems, L.L.C. Heat engine system including an integrated cooling circuit
US11324816B2 (en) * 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
US10688175B2 (en) 2015-10-13 2020-06-23 Daniel C. Carter NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
PT3718565T (pt) 2015-10-22 2022-07-20 Modernatx Inc Vacinas contra vírus respiratórios
JP7311872B2 (ja) 2015-10-29 2023-07-20 エモリー ユニバーシティー キメラｒｓｖ、免疫原性組成物、及び使用方法
EP3393512B1 (en) 2015-12-23 2025-11-19 Pfizer Inc. Rsv f protein mutants
US11174292B2 (en) 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
MA52910A (fr) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention Bv Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2018005558A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
EP3606942B1 (en) 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN107157933B (zh) 2017-05-04 2021-05-11 同济大学 一种蛋白自组装新型纳米疫苗及其制备方法
KR20250067954A (ko) * 2018-02-28 2025-05-15 유니버시티 오브 워싱톤 자기 조립 나노구조 백신

Also Published As

Publication number Publication date
AU2022202787A1 (en) 2022-05-19
US11732011B2 (en) 2023-08-22
CN115779077A (zh) 2023-03-14
JP7168938B2 (ja) 2022-11-10
SI3606942T1 (sl) 2025-11-28
EP4559869A3 (en) 2025-08-20
JP2023002680A (ja) 2023-01-10
EP3606942A1 (en) 2020-02-12
SMT202500317T1 (it) 2025-11-10
US20220169681A1 (en) 2022-06-02
RU2019130167A3 (es) 2021-12-22
PT3606942T (pt) 2025-09-01
DK3606942T3 (da) 2025-09-08
CN110603262A (zh) 2019-12-20
AU2022202787C1 (en) 2025-01-30
PL3606942T3 (pl) 2025-11-12
AU2018249533C1 (en) 2023-10-12
WO2018187325A1 (en) 2018-10-11
EP3606942B1 (en) 2025-06-11
JP2020515280A (ja) 2020-05-28
EP4559869A2 (en) 2025-05-28
FI3606942T3 (fi) 2025-08-29
US20240150411A1 (en) 2024-05-09
JP7541701B2 (ja) 2024-08-29
RU2019130167A (ru) 2021-05-05
US20200392187A1 (en) 2020-12-17
PH12019502276A1 (en) 2020-09-28
CA3058794A1 (en) 2018-10-11
IL269643A (en) 2019-11-28
RS67190B1 (sr) 2025-10-31
HRP20251060T1 (hr) 2025-11-07
LT3606942T (lt) 2025-10-10
SG11201908999QA (en) 2019-10-30
AU2024220089A1 (en) 2024-10-17
KR20240161683A (ko) 2024-11-12
CN115947873A (zh) 2023-04-11
AU2018249533B2 (en) 2022-01-27
AU2018249533A1 (en) 2019-10-17
ES3040563T3 (en) 2025-11-03
IL322023A (en) 2025-09-01
KR102774312B1 (ko) 2025-03-05
JP2024160321A (ja) 2024-11-13
US12275757B2 (en) 2025-04-15
MX2023004704A (es) 2023-05-09
KR20190140916A (ko) 2019-12-20
AU2022202787B2 (en) 2024-07-04
US20250263445A1 (en) 2025-08-21
BR112019020661A2 (pt) 2020-05-05
US11192926B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
MX2019011869A (es) Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
MX2016008958A (es) Proteinas quimericas de factor viii y usos de estas.
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
AR123115A1 (es) Composiciones y métodos para la degradación selectiva de proteínas
EP3729560A4 (en) REFLECTOR SYSTEMS FEEDED BY PHASE-CONTROLLED GROUP ANTENNA WITH WIDE SCAN
CL2021000432A1 (es) Aparatos de marco aislable y aislante y métodos de fabricación y uso de los mismos
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
MX2018005063A (es) Polipéptidos condicionalmente activos.
MX2018012814A (es) Métodos para modular selectivamente la actividad de distintos sub-tipos de células.
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
UY40283A (es) Método para alterar una propiedad de una planta
MX2019005325A (es) Matriz para el crecimiento de celulas.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
JP2014132019A5 (es)
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112016024494A8 (pt) análogo de peptídeo e seu uso
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
AR106796A1 (es) Apuntalante de peso liviano y métodos para su producción y uso
CL2020000862A1 (es) Composición de proteína de guisante con calidad nutricional mejorada.